Literature DB >> 11076691

Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades.

K Chiba1, A Sugiyama, Y Satoh, H Shiina, K Hashimoto.   

Abstract

Drug-induced prolongation of the QT interval is often associated with the onset of Torsades de Pointes (TdP) resulting in a life-threatening ventricular arrhythmia. The potential of the proarrhythmic effects of the new fluoroquinolone antibacterial agents, levofloxacin and sparfloxacin, was examined in the chronic complete atrioventricular block dogs with stable idioventricular automaticity using Holter ECG monitoring in conscious state (Experiment 1). Next, to better analyze the mechanisms of the proarrhythmic property, the cardiovascular effects of these two drugs were compared in the halothane-anesthetized dogs under the monitoring of ECG, His bundle electrogram, systemic and left ventricular pressure, monophasic action potential, cardiac output, and effective refractory period (Experiment 2). In Experiment 1, oral administration of 6 mg/kg (n = 4) as well as 60 mg/kg (n = 4) of levofloxacin did not induce any ventricular premature depolarization. On the other hand, oral administration of 60 mg/kg of sparfloxacin (n = 4) induced TdP leading to ventricular fibrillation in all animals within 24 h, while 6 mg/kg of sparfloxacin (n = 4) did not induce any ventricular premature depolarization. In Experiment 2, intravenous administration of 0.3 mg/kg as well as 3.0 mg/kg of levofloxacin slightly increased cardiac output, but no significant changes were detected in the other parameters (n = 6). On the other hand, intravenous administration of 0.3 mg/kg of sparfloxacin prolonged the effective refractory period. Additional administration of 3.0 mg/kg of sparfloxacin decreased the heart rate and prolonged the effective refractory period and ventricular repolarization phase in a similar extent, but no significant changes were detected in the other parameters (n = 6). These results suggest that backward shift of the relative repolarization period in a cardiac cycle may be the mechanism responsible for the torsadegenic effect of sparfloxacin. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11076691     DOI: 10.1006/taap.2000.9041

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  7 in total

1.  Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2.

Authors:  G Eichenbaum; M K Pugsley; D J Gallacher; R Towart; G McIntyre; U Shukla; J M Davenport; H R Lu; J Rohrbacher; V Hillsamer
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

2.  The anaesthetized rabbit with acute atrioventricular block provides a new model for detecting drug-induced Torsade de Pointes.

Authors:  Mihoko Hagiwara; Seiji Shibuta; Kazuhiro Takada; Ryuichi Kambayashi; Misako Nakajo; Megumi Aimoto; Yoshinobu Nagasawa; Akira Takahara
Journal:  Br J Pharmacol       Date:  2017-07-05       Impact factor: 8.739

Review 3.  Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Authors:  Gerrit Frommeyer; Lars Eckardt
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419

4.  Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects.

Authors:  D A Gajjar; A Bello; Z Ge; L Christopher; D M Grasela
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 5.  Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts.

Authors:  A Sugiyama
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

6.  Pharmacometabolomic approach to predict QT prolongation in guinea pigs.

Authors:  Jeonghyeon Park; Keumhan Noh; Hae Won Lee; Mi-sun Lim; Sook Jin Seong; Jeong Ju Seo; Eun-Jung Kim; Wonku Kang; Young-Ran Yoon
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

Review 7.  The canine chronic atrioventricular block model in cardiovascular preclinical drug research.

Authors:  Vera Loen; Marc A Vos; Marcel A G van der Heyden
Journal:  Br J Pharmacol       Date:  2021-05-04       Impact factor: 9.473

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.